India Fat-Loss Drug Sales Slow After Early Spike From Generics
Growth in India’s obesity- and diabetes-drug market is losing steam just months after a surge triggered by the arrival of generic semaglutide products.
By Satviki Sanjay · Bloomberg Markets
Growth in India’s obesity- and diabetes-drug market is losing steam just months after a surge triggered by the arrival of generic semaglutide products.